SK281737B6 - 2-fenylindolové zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie - Google Patents

2-fenylindolové zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie Download PDF

Info

Publication number
SK281737B6
SK281737B6 SK472-97A SK47297A SK281737B6 SK 281737 B6 SK281737 B6 SK 281737B6 SK 47297 A SK47297 A SK 47297A SK 281737 B6 SK281737 B6 SK 281737B6
Authority
SK
Slovakia
Prior art keywords
benzyl
methyl
ethoxy
compound
pharmaceutically acceptable
Prior art date
Application number
SK472-97A
Other languages
English (en)
Slovak (sk)
Other versions
SK47297A3 (en
Inventor
Chris Paul Miller
Michael David Collini
Bach Dinh Tran
Arthur Attilio Santilli
Original Assignee
American Home Products Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27092026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK281737(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/833,271 external-priority patent/US5998402A/en
Application filed by American Home Products Corporation filed Critical American Home Products Corporation
Publication of SK47297A3 publication Critical patent/SK47297A3/sk
Publication of SK281737B6 publication Critical patent/SK281737B6/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SK472-97A 1996-04-19 1997-04-15 2-fenylindolové zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie SK281737B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63397496A 1996-04-19 1996-04-19
US08/833,271 US5998402A (en) 1996-04-19 1997-04-04 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents

Publications (2)

Publication Number Publication Date
SK47297A3 SK47297A3 (en) 1997-11-05
SK281737B6 true SK281737B6 (sk) 2001-07-10

Family

ID=27092026

Family Applications (1)

Application Number Title Priority Date Filing Date
SK472-97A SK281737B6 (sk) 1996-04-19 1997-04-15 2-fenylindolové zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie

Country Status (26)

Country Link
EP (1) EP0802183B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4093611B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100480193B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1106383C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR011503A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE206701T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU710149B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI9715334B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO4900051A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY2325B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ291701B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE69707189T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0802183T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA001448B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2162198T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR09C0048I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU227077B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL120701A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU91608I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9702865A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300416I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO309564B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ314601A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT802183E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK281737B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA48148C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1011666A4 (en) * 1997-04-30 2004-03-31 Lilly Co Eli ANTITHROMBOTIC AGENTS
WO1998048800A1 (en) 1997-05-01 1998-11-05 Eli Lilly And Company Antithrombotic agents
ID24568A (id) * 1997-11-06 2000-07-27 American Home Prod Kontrasepsi oral yang mengandung anti-estrogen plus progestin
ATE339415T1 (de) * 1998-05-12 2006-10-15 Wyeth Corp Benzocarbazol und indenoindole derivate als östrogene agentien
US6069153A (en) * 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
JP2002515484A (ja) * 1998-05-15 2002-05-28 アメリカン・ホーム・プロダクツ・コーポレイション 2−フェニルインドール化合物およびエストロゲン製剤からなる組成物
CN1230163C (zh) * 1998-05-15 2005-12-07 惠氏公司 与雌激素联合的2-苯基-1-[4-(2-氨基乙氧基)-苄基]-吲哚
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
DE69914563T2 (de) 1998-10-30 2004-12-16 Eli Lilly And Co., Indianapolis Azaindol derivate und ihre Verwendung als antithrombotische Wirkstoffe
TWI220898B (en) * 1999-03-04 2004-09-11 Wyeth Corp N-substituted indolines as estrogenic agents
EP1159268A1 (en) * 1999-03-04 2001-12-05 American Home Products Corporation N-SUBSTITUTED BENzOYL INDOLES AS ESTROGENIC AGENTS
US6380185B1 (en) 1999-03-04 2002-04-30 American Home Products Corporation N-substituted benzoyl indoles as estrogenic agents
US6358943B1 (en) 1999-03-04 2002-03-19 American Home Products Corporation N-substituted indolines as estrogenic agents
US6380166B1 (en) 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
IL148273A0 (en) * 1999-09-13 2002-09-12 American Cyanamid Co Glucopyranoside conijugates of 2-(4-hydroxy-phenyl)-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1h-indol-5-ols
IL149990A0 (en) * 2000-01-28 2002-12-01 Endorech Inc Selective estrogen receptor modulators in combination with estrogens
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US20020016318A1 (en) * 2000-07-06 2002-02-07 American Home Products Corporation Methods of treating breast disorders
CA2414938A1 (en) * 2000-07-06 2002-01-17 Simon Nicholas Jenkins Combinations of ssri and estrogenic agents
EP1656938A1 (en) 2000-07-06 2006-05-17 Wyeth Combinations of SSRI and estrogenic agents
AU2001271784A1 (en) * 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
WO2002003990A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted insole compounds for treating excessive intraocular pressure
US6358991B2 (en) * 2000-07-06 2002-03-19 American Home Products Corporation Methods of treating neuropeptide Y-related conditions
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
WO2002003989A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating sphincter incontinence
US20020022617A1 (en) * 2000-07-06 2002-02-21 American Home Products Corporation Methods for increasing nitric oxide synthase activity
AR030064A1 (es) * 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
EP1177787A3 (en) * 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
WO2002094788A1 (en) 2001-05-22 2002-11-28 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
JP2004531559A (ja) 2001-05-22 2004-10-14 イーライ・リリー・アンド・カンパニー エストロゲン欠乏または内因性エストロゲンに対する異常な生理反応に関連する疾患を抑制するためのテトラヒドロキノリン誘導体
CA2489098A1 (en) * 2002-06-13 2003-12-24 Wyeth Bazedoxifene treatment regimens
US7399867B2 (en) 2002-07-22 2008-07-15 Eli Lilly And Company Selective estrogen receptor modulators containing a phenylsulfonyl group
CA2512000C (en) 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
US7250440B2 (en) * 2003-08-12 2007-07-31 Wyeth (Hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivatives as estrogenic agents
RU2006132352A (ru) 2004-04-07 2008-05-20 Вайет (Us) Кристаллическая полиморфная форма базедоксифен ацетата
WO2005100316A1 (en) 2004-04-07 2005-10-27 Wyeth Crystalline polymorph of a bazedoxifene acetate
US7504394B2 (en) 2004-04-08 2009-03-17 Wyeth Bazedoxifene ascorbate
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CA2573185A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
JP2008507518A (ja) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス,インコーポレーテッド C型肝炎を治療するためのチエノピリジン
MX2007001506A (es) * 2004-08-05 2007-03-27 Wyeth Corp Polimorfo cristalino del clorhidrato de pipindoxifeno monohidratado.
AP2365A (en) 2004-10-20 2012-02-20 Endorech Inc Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 CGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women.
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
US20100087661A1 (en) * 2007-02-12 2010-04-08 Josef Jirman Method for the preparation of 5-benzyloxy-2-(4-benzyloxphenyl)-3-methyl-1h-indole
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
KR20100113627A (ko) * 2008-02-11 2010-10-21 와이어쓰 엘엘씨 바제독시펜 아세테이트의 다형체 형태 a의 제조방법
CA2720215C (en) 2008-04-16 2018-02-27 Karo Bio Ab Estrogen receptor ligands
RU2011145811A (ru) * 2009-04-13 2013-05-20 Сандоз Аг Способы синтеза базедоксифенацетата и его промежуточных продуктов
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
ITMI20091109A1 (it) * 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
KR20170127044A (ko) 2010-06-16 2017-11-20 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
US7968732B1 (en) 2010-09-07 2011-06-28 Divi's Laboratories, Ltd. Process for the preparation of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole
US9212172B2 (en) 2010-09-14 2015-12-15 Dr. Reddy's Laboratories Limited Preparation of crystalline bazedoxifene and its salts
US8569483B2 (en) 2011-06-21 2013-10-29 Divi's Laboratories, Ltd. Process for the preparation of bazedoxifene acetate and intermediates thereof
CN102690225B (zh) * 2012-04-11 2014-12-24 南京友杰医药科技有限公司 巴多昔芬的合成方法
WO2014186325A1 (en) * 2013-05-15 2014-11-20 Indiana University Research And Technology Corporation Processes and intermediates for preparing indole pharmaceuticals
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
ES2939940T3 (es) 2014-03-28 2023-04-28 Univ Duke Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
US9845291B2 (en) * 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
KR20190110400A (ko) 2018-03-20 2019-09-30 엠에프씨 주식회사 새로운 중간체를 이용한 바제독시펜의 제조방법
IT201800006562A1 (it) * 2018-06-21 2019-12-21 Procedimento e intermedi utili per la preparazione di indoli
IT201900001923A1 (it) 2019-02-11 2020-08-11 Erregierre Spa Sali di bazedoxifene utili per la preparazione di bazedoxifene acetato
US11246874B1 (en) 2021-04-20 2022-02-15 Oxygen Biotech LLC Treatment of COVID-19

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU373940A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1970-01-21 1973-03-12
DE2557342A1 (de) * 1975-12-19 1977-06-30 Hoechst Ag Basisch substituierte indolderivate und verfahren zu ihrer herstellung
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
DE3232968A1 (de) * 1981-09-10 1983-06-09 Degussa Ag, 6000 Frankfurt Neue 2-(hydroxy-phenyl)-indole und verfahren zu deren herstellung
CA1241660A (en) * 1984-06-25 1988-09-06 Yvan Guindon Indole-2-alkanoic acids
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
DE3821148A1 (de) * 1988-06-23 1989-12-28 Erwin Von Dr Angerer Aminoalkylindole, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
GB9004301D0 (en) * 1990-02-26 1990-04-18 Fujisawa Pharmaceutical Co Indolebutyric acid derivatives and process for preparation thereof
US5051442A (en) * 1990-04-25 1991-09-24 Merrell Dow Pharmaceuticals Inc. 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof
AU665690B2 (en) * 1992-05-08 1996-01-11 Otsuka Pharmaceutical Factory, Inc. Indole derivative
EP0634169B1 (en) * 1993-06-29 2000-01-05 Takeda Chemical Industries, Ltd. Quinoline or quinazoline derivatives and their use in the manufacture of a medicament for the treatment of osteoporosis
GB9326332D0 (en) * 1993-12-23 1994-02-23 Karo Bio Indole derivatives
DE4426625A1 (de) * 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln

Also Published As

Publication number Publication date
IL120701A (en) 2005-09-25
DE69707189D1 (de) 2001-11-15
LU91608I2 (fr) 2009-11-23
BRPI9715334B8 (pt) 2021-05-25
EA001448B1 (ru) 2001-04-23
HUP9700777A2 (hu) 1999-06-28
JPH1036346A (ja) 1998-02-10
CZ117597A3 (en) 1997-11-12
IL120701A0 (en) 1997-09-30
FR09C0048I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2010-06-11
NO971815D0 (no) 1997-04-18
NO2009025I2 (no) 2010-11-22
HU9700777D0 (en) 1997-06-30
ATE206701T1 (de) 2001-10-15
KR100480193B1 (ko) 2005-08-30
UA48148C2 (uk) 2002-08-15
CZ291701B6 (cs) 2003-05-14
NO309564B1 (no) 2001-02-19
DE69707189T2 (de) 2002-06-20
MX9702865A (es) 1998-05-31
AU1892097A (en) 1997-10-23
NO2009025I1 (no) 2009-11-30
AU710149B2 (en) 1999-09-16
HUP9700777A3 (en) 2000-04-28
CY2009016I2 (el) 2010-07-28
NL300416I1 (nl) 2009-12-01
HK1002863A1 (en) 1998-09-25
BR9715334B1 (pt) 2012-09-04
AR011503A1 (es) 2000-08-30
ES2162198T3 (es) 2001-12-16
EP0802183B1 (en) 2001-10-10
EP0802183A1 (en) 1997-10-22
HU227077B1 (en) 2010-06-28
CY2009016I1 (el) 2010-07-28
CN1170719A (zh) 1998-01-21
JP4093611B2 (ja) 2008-06-04
CY2325B1 (en) 2003-11-14
FR09C0048I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2009-06-11
SK47297A3 (en) 1997-11-05
DE122009000061I1 (de) 2009-12-31
CO4900051A1 (es) 2000-03-27
KR970069037A (ko) 1997-11-07
NZ314601A (en) 1999-09-29
NL300416I2 (nl) 2010-02-01
CN1106383C (zh) 2003-04-23
PT802183E (pt) 2002-03-28
DK0802183T3 (da) 2002-02-04
NO971815L (no) 1997-10-20
EA199700044A1 (ru) 1997-12-30

Similar Documents

Publication Publication Date Title
SK281737B6 (sk) 2-fenylindolové zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie
US6225308B1 (en) Tissue selective compounds in the treatment of prostate cancer or benign prostate hypertrophy
US20030203883A1 (en) 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
SK284666B6 (sk) Farmaceutický prostriedok obsahujúci indolové zlúčeniny a estrogény a jeho použitie
CA2203078C (en) 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]indoles as estrogenic agents
HK1002863B (en) Estrogenic agents
CA2558821A1 (en) 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]indoles as estrogenic agents
MXPA00011178A (en) 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20170415